Shore Capital Partners has teamed up with US-based device company C2Dx, to acquire Cook Medical’s family of Otolaryngology – Head and Neck Surgery (OHNS) products.
Cook’s OHNS products are used by ear, nose, and throat (ENT) surgeonsfor various conditions such as salivary disease, chronic ear disorders, nasal/sinus and skull base reconstruction, and dysphagia.
Products in the portfolio include salivary access and intervention tools, as well as its Biodesign Sinonasal repair graft designed for use during nasal and sinus mucosal tissue procedures.
The companies have not yet disclosed the value of the acquisition.
In November of last year, CooperCompanies acquired $300m worth of medical devices from Cook, including minimally invasive Doppler monitoring, obstetrics, and gynaecology surgery devices.
This deal came three months after CooperCompanies abandoned plans to acquire Cook Medical’s reproductive health business for $875m, following a full-phase investigation by the US Federal Trade Commission (FTC).
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
Your download email will arrive shortly
We are confident about the
quality of our Company Profiles. However, we want you to make the most
decision for your business, so we offer a free sample that you can download by
submitting the below form
CooperCompanies agreed to acquire Cook Medical to enhance its reproductive health portfolio in 2022, however the FTC emphasised the importance of market competition in a statement and engaged regulators in Australia and the UK to investigate the deal, leading to the subsequent abandonment of the deal.
In the announcement accompanying the collaboration, C2Dx CEO Kevin McLeod said: “Our partnership will enable us to invest further in our team, capabilities, and offerings, so we can grow faster and continue providing excellent service and products to our customers.
“Our acquisition of Cook’s OHNS product family is transformative for C2Dx, and consistent with the strategy we developed when we partnered with Shore.”
Founded in 2019, Michigan-headquartered C2Dx has its own surgical device portfolio, including the Shaw scalpel which it acquired from Hemostatix Medical Technologies in 2022. The scalpel seals blood vessels as they are cut.
In September 2023, Galen Robotics received De Novo authorisation from US Food and Drug Administration (FDA) for its robotic system used in ENT surgical procedures including instrument placement along with microlaryngeal alligator forceps.